Mosaic Immunoengineering Inc
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. It engages in pursuing new product candidates and platforms to build a new pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
Mosaic Immunoengineering Inc (CPMV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, Mosaic Immunoengineering Inc (CPMV) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.82K) by net assets ($-7.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mosaic Immunoengineering Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mosaic Immunoengineering Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mosaic Immunoengineering Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mosaic Immunoengineering Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FendX Technologies Inc.
PINK:FDXTF
|
0.069x |
|
Reliant Holdings Inc
OTCQB:RELT
|
1.428x |
|
Dongbu HiTek Co. Ltd.
KQ:000990
|
N/A |
|
Imperial Pacific Ltd
AU:IPC
|
0.024x |
|
BUZZI UNICEM
BE:UCM
|
N/A |
|
Busan Industrial Co. Ltd.
KQ:011390
|
N/A |
|
Libental
TA:LBTL
|
-2.455x |
|
Lingo Media Corporation
PINK:LMDCF
|
-0.161x |
Annual Cash Flow Conversion Efficiency for Mosaic Immunoengineering Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mosaic Immunoengineering Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.79 Million | $-241.16K | 0.036x | -58.07% |
| 2023-12-31 | $-5.87 Million | $-497.47K | 0.085x | -40.03% |
| 2022-12-31 | $-4.88 Million | $-690.13K | 0.141x | -41.78% |
| 2021-12-31 | $-2.80 Million | $-679.24K | 0.243x | -76.36% |
| 2020-12-31 | $-422.54K | $-433.78K | 1.027x | +21664.83% |
| 2019-12-31 | $636.02K | $3.00K | 0.005x | +101.05% |
| 2018-12-31 | $1.70 Million | $-760.77K | -0.448x | -27.10% |
| 2017-12-31 | $2.50 Million | $-880.29K | -0.353x | +0.29% |
| 2016-12-31 | $3.70 Million | $-1.31 Million | -0.354x | -- |